Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANIP Stock Summary
Top 10 Correlated ETFs
In the News
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows:
ANI Pharmaceuticals, Inc. (ANIP) Q3 2023 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Les Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Operator Good day, everyone, and welcome to the ANI Pharmaceuticals, Inc. Third Quarter 2023 Earnings Results Call.
ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note
ANI Pharmaceuticals (ANIP) closed at $61.66 in the latest trading session, marking a -0.13% move from the prior day.
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.
ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know
ANI Pharmaceuticals (ANIP) closed at $57.44 in the latest trading session, marking a +0.23% move from the prior day.
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why
The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close.
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York City as follows:
Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio
ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.
ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes ANI (ANIP) a New Strong Buy Stock
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANIP Financial details
ANIP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||17.26||17.44||17.43||17.16||19.46|
|Net income per share||1.33||0.51||-1.88||-3.38||-2.95|
|Operating cash flow per share||5.74||3.85||1.28||0.26||-1.92|
|Free cash flow per share||4.81||1.53||-4.43||-1.61||-2.93|
|Cash per share||3.68||5.26||0.66||7.96||2.97|
|Book value per share||16.89||17.97||16.36||28.48||20.82|
|Tangible book value per share||-0.68||2.43||0.3||2.92||3.61|
|Share holders equity per share||16.89||17.97||16.36||28.48||20.82|
|Interest debt per share||16.94||16.78||16.31||23.76||19.35|
|Price to sales ratio||2.61||3.54||1.67||2.69||2.07|
|EV to sales||3.3||4.13||2.52||3.55||2.82|
|Enterprise value over EBITDA||9.71||14.04||18.38||52.07||27.97|
|EV to operating cash flow||9.92||18.71||34.4||231.03||-28.6|
|EV to free cash flow||11.85||47.21||-9.9||-37.78||-18.73|
|Free cash flow yield||0.11||0.02||-0.15||-0.04||-0.07|
|Debt to equity||0.93||0.87||0.95||0.8||0.85|
|Debt to assets||0.43||0.41||0.4||0.37||0.38|
|Net debt to EBITDA||2.04||2.03||6.22||12.69||7.47|
|Sales general and administrative to revenue||0.22||0||0||0||0|
|Research and developement to revenue||0.08||0.1||0.08||0.05||0.07|
|Intangibles to total assets||0.48||0.4||0.42||0.42||0.37|
|Capex to operating cash flow||-0.16||-0.6||-4.48||-7.12||0.53|
|Capex to revenue||-0.05||-0.13||-0.33||-0.11||-0.05|
|Capex to depreciation||-0.32||-0.62||-1.53||-0.5||-0.28|
|Stock based compensation to revenue||0.03||0.04||0.06||0.05||0.05|
|Return on tangible assets||0.07||0.02||-0.08||-0.09||-0.1|
|Tangible asset value||-7.92M||28.82M||3.61M||36.73M||58.68M|
|Net current asset value||-80.46M||-56.3M||-95.17M||-91.08M||-77.29M|
|Days sales outstanding||117.41||127.46||167.72||217.05||190.86|
|Days payables outstanding||44.41||84.42||47.16||83.32||77.07|
|Days of inventory on hand||202.45||278.36||254.63||296.37||277.08|
|Capex per share||-0.93||-2.33||-5.71||-1.88||-1.01|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||5.14||5.77||6.51||6.59||6.98|
|Net income per share||-0.53||-0.26||0.09||0.35||0.53|
|Operating cash flow per share||0.22||-0.27||1.31||1.17||1.7|
|Free cash flow per share||-0.38||-0.46||1.16||0.78||1.46|
|Cash per share||3.45||2.95||4.13||9.14||10.22|
|Book value per share||20.65||20.74||20.71||24.56||24.08|
|Tangible book value per share||2.71||3.59||4.42||9.95||10.94|
|Share holders equity per share||20.65||20.74||20.71||24.56||24.08|
|Interest debt per share||18.03||18.01||17.94||16.58||15.48|
|Price to sales ratio||6.25||6.97||6.1||8.17||8.32|
|EV to sales||9||9.5||8.14||9.24||9.02|
|Enterprise value over EBITDA||52.36||46.01||32.63||38.34||38.91|
|EV to operating cash flow||208.23||-203.42||40.59||52.19||36.97|
|EV to free cash flow||-121.86||-118.67||45.6||78.01||43.06|
|Free cash flow yield||-0.01||-0.01||0.03||0.01||0.03|
|Debt to equity||0.85||0.85||0.84||0.66||0.63|
|Debt to assets||0.39||0.38||0.37||0.33||0.32|
|Net debt to EBITDA||15.99||12.25||8.2||4.43||3.04|
|Sales general and administrative to revenue||0||0||0||0||0|
|Research and developement to revenue||0.09||0.06||0.06||0.06||0.08|
|Intangibles to total assets||0.4||0.37||0.35||0.3||0.28|
|Capex to operating cash flow||-2.71||0.71||-0.11||-0.33||-0.14|
|Capex to revenue||-0.12||-0.03||-0.02||-0.06||-0.03|
|Capex to depreciation||-0.64||-0.2||-0.16||-0.46||-0.3|
|Stock based compensation to revenue||0.05||0.04||0.04||0.05||0.04|
|Return on tangible assets||-0.02||-0.01||0||0.01||0.02|
|Tangible asset value||44.22M||58.68M||72.47M||175.95M||206.66M|
|Net current asset value||-93.06M||-77.29M||-60.99M||34.44M||62.02M|
|Days sales outstanding||150.79||158.01||147.25||133.54||122.1|
|Days payables outstanding||51.96||72.61||78.02||60.67||63.76|
|Days of inventory on hand||262.37||261.02||247.4||222.05||199.44|
|Capex per share||-0.6||-0.19||-0.14||-0.39||-0.24|
ANIP Frequently Asked Questions
What is ANI Pharmaceuticals, Inc. stock symbol ?
ANI Pharmaceuticals, Inc. is a US stock , located in Baudette of Mn and trading under the symbol ANIP
Is ANI Pharmaceuticals, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $48. The lowest prediction is $48 and the highest is $48
What is ANIP stock prediction ?
What is ANI Pharmaceuticals, Inc. stock quote today ?
ANI Pharmaceuticals, Inc. stock price is $48.94 today.
Is ANI Pharmaceuticals, Inc. stock public?
Yes, ANI Pharmaceuticals, Inc. is a publicly traded company.